BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Cytiva expands Fast Trakâ?¢ process development and validation services facility in India

25 February 2026 | News

Supports multiple modalities including mAbs, pDNA/mRNA, recombinant proteins, and viral vectors



Cytiva, a Danaher company and a leader in the life sciences industry, has inaugurated an expanded facility for Fast Trak process development (PD) and validation services in Bengaluru.

The centre will help biopharma companies in India and across Asia-Pacific shorten development timelines, reduce manufacturing risk, and scale confidently—as India aims to grow its bioeconomy to $300 billion by 2030.

The ~30 000 sq ft facility brings together upstream and downstream process development, optimisation and scale-up, and validation services under one roof. It also offers immersive training to provide customers with the knowledge and skills to accelerate their molecule-to-market journey.

Pierre-Alain Ruffieux, Chief Operating Officer, Cytiva, said “India’s scientific strength plays a vital role in global biopharma, and this facility reinforces that momentum. By expanding our capabilities here, we’re giving customers the infrastructure to move from idea to impact with greater speed, reliability, and excellence.”

Manoj Panicker, General Manager, Cytiva South Asia, said “This facility will enable our customers to innovate faster while maintaining complete control of their processes—improving access to life-saving medicines. This is especially critical for rare diseases, emerging modalities, and the growing biosimilars market, where speed and flexibility are essential.”

According to Cytiva's 2025 Biopharma Index, 56% of global biopharma executives agree that domestic manufacturing of biologics is set to increase dramatically over the next three years. This is especially apparent in India, where demand for biologics and biosimilars is rising and customers increasingly need localised expertise with global quality standards.

Deployed in a GLP-compliant biosafety level 2 (BSL-2) environment, Cytiva’s PD solutions at Fast Trak India are designed for singleâ??use bioreactor scale up to 200L and can produce toxicity batch material to support preclinical stages. The ISOâ??certified validation lab provides specialised testing and documentation services for sterilizing grade filters and single-use system needs.